Research and Practice in Thrombosis and Haemostasis

Article	Citations
Prothrombotic changes in patients with COVID‐19 are associated with disease severity and mortality	70
Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT)	58
Sexism in the management of bleeding disorders	57
Tranexamic acid evidence and controversies: An illustrated review	56
The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study	49
Risk of thrombotic complications in influenza versus COVID‐19 hospitalized patients	48
Comparison of the coagulopathies associated with COVID‐19 and sepsis	41
Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis	39
Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries	36
The role of platelets in sepsis	35
Validation of the IMPROVE‐DD risk assessment model for venous thromboembolism among hospitalized patients with COVID‐19	35
Abstract	35
Protease‐activated receptors: An illustrated review	35
Abstracts	33
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)	32
Hormonal therapies and venous thrombosis: Considerations for prevention and management	31
The psychological impact of pulmonary embolism: A mixed‐methods study	30
Blood clot contraction: Mechanisms, pathophysiology, and disease	28
Visualizing thrombosis to improve thrombus resolution	26
Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set	25
Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE	25
Impact of novel hemophilia therapies around the world	25
Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants	25
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment	24
Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation	23

Living with a “hemophilia‐free mind” – The new ambition of hemophilia care?	23
A call to action for anticoagulation stewardship	22
Viscoelastic testing: an illustrated review of technology and clinical applications	22
Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting	22
Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)	22
Acquired von Willebrand syndrome in monoclonal gammopathy – A scoping review on hemostatic management	22
Platelets in the neonate: Not just a small adult	21
Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors	19
Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma	19
Fibrinolysis: an illustrated review	19
Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial	19
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts	19
Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease	18
Direct oral anticoagulants for unusual‐site venous thromboembolism	18
MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia	17
Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern	17
COVID‐19 and venous thromboembolism: A narrative review	16
Caging the dragon: Research approach to COVID‐19–related thrombosis	16
Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors	16
Thrombotic microangiopathies: An illustrated review	16
Vaccine‐induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine–A case report	16
Diagnosis and follow‐up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay	16
DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples	16
Novel mechanisms of thrombo-inflammation during infection: spotlight on neutrophil extracellular trap-mediated platelet activation	15
GPIbα is the driving force of hepatic thrombopoietin generation	15
Social determinants of health in pulmonary embolism management and outcome in hospitals: Insights from the United States nationwide inpatient sample	15
Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination	15
D‐dimer testing in clinical practice in the era of COVID‐19	15
Physical forces regulating hemostasis and thrombosis: Vessels, cells, and molecules in illustrated review	15
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method	14
Platelet‐leukocyte interactions in COVID‐19: Contributions to hypercoagulability, inflammation, and disease severity	14
A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding	14
Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status	14
A call to action: MTHFR polymorphisms should not be a part of inherited thrombophilia testing	13
Building a better NET: Neutrophil extracellular trap targeted therapeutics in the treatment of infectious and inflammatory disorders	13
Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report	13
Hemostasis and fibrinolysis in COVID‐19 survivors 6 months after intensive care unit discharge	13
Epidemiology of cerebral venous sinus thrombosis and cerebral venous sinus thrombosis with thrombocytopenia in the United States, 2018 and 2019	13
ST Genesia reference values of 117 healthy donors measured with STG‐BleedScreen, STG‐DrugScreen and STG‐ThromboScreen reagents	13
Disseminated intravascular coagulation diagnosis: Positive predictive value of the ISTH score in a Danish population	13
The intersection of vector biology, gene therapy, and hemophilia	13
Pulmonary embolism and deep venous thrombosis after COVID-19: long-term risk in a population-based cohort study	12
Pulmonary embolism and deep vein thrombosis—comorbidities and temporary provoking factors in a register‐based study of 1.48 million people	12
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study	12
Neutrophil extracellular trap regulators in sickle cell disease: Modulation of gene expression of PADI4, neutrophil elastase, and myeloperoxidase during vaso‐occlusive crisis	12
Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study	12
Mechanisms of cancer-associated thrombosis	12
Health‐related quality‐of‐life questionnaires for deep vein thrombosis and pulmonary embolism: A systematic review on questionnaire development and methodology	12
Developing and optimizing a computable phenotype for incident venous thromboembolism in a longitudinal cohort of patients with cancer	12
The lived experience of women with a bleeding disorder: A systematic review	12

Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review	12
Venous thromboembolism after lower extremity orthopedic surgery: A population‐based nationwide cohort study	12
The ongoing enigma of SARS‐CoV‐2 and platelet interaction	12
How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study	12
Prevalence of thrombocytopenia, anti–platelet factor 4 antibodies and D‐dimer elevation in Thai people After ChAdOx1 nCoV‐19 vaccination	11
The venous thrombosis registry in Østfold Hospital (TROLL registry) ‐ design and cohort description	11
Use of rotational thromboelastometry to predict hemostatic complications in pediatric patients undergoing extracorporeal membrane oxygenation: A retrospective cohort study	11
Respective roles of Glycoprotein VI and FcγRIIA in the regulation of αIIbβ3‐mediated platelet activation to fibrinogen, thrombus buildup, and stability	11
Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies	11
Patient selection for hemophilia gene therapy: Real‐life data from a single center	11
Quality of life in adolescents with heavy menstrual bleeding: Validation of the Adolescent Menstrual Bleeding Questionnaire (aMBQ)	11
Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study	11
Disparities in obstetric hemorrhage outcomes	11
Aspirin at 120: Retiring, recombining, or repurposing?	11
Deterioration of vaccine‐induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: Insight from functional cytometry and serotonin release assay	10
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B	10
ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin‐6	10
Menstruation, anticoagulation, and contraception: VTE and uterine bleeding	10
ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso‐occlusive crisis of sickle cell disease	10
Severe COVID‐19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis	10
Prevalence of anti–platelet factor 4/polyanionic antibodies after COVID‐19 vaccination with ChAdOx1 nCoV‐19 and CoronaVac in Thais	10
Sex‐specific aspects of venous thromboembolism: What is new and what is next?	10
Racial differences in protein S Tokushima and two protein C variants as genetic risk factors for venous thromboembolism	10
The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy	10
Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing – Evaluation on spiked and patient samples	10
Optimization of DOAC management services in a centralized anticoagulation clinic	10
Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation	10
Global coagulation assays in patients with diabetes mellitus	10
Acquired hemophilia following COVID‐19 vaccination: Case report and review of literature	10
Anti‐platelet factor 4 immunoglobulin G levels in vaccine‐induced immune thrombocytopenia and thrombosis: Persistent positivity through 7 months	10
Antithrombin-lowering in hemophilia: a closer look at fitusiran	10
Fibrinogen concentrate for bleeding in patients with congenital fibrinogen deficiency: Observational study of efficacy and safety for prophylaxis and treatment	10
Vaccine‐induced immune thrombotic thrombocytopenia presenting with normal platelet count	9
Recanalization and outcomes after cerebral venous thrombosis: a systematic review and meta-analysis	9
Coagulation biomarkers for ischemic stroke	9
Heparin-induced thrombocytopenia: An illustrated review	9
Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin	9
Communication at diagnosis of venous thromboembolism: Lasting impact of verbal and nonverbal provider communication on patients	9
Neutrophils in lung cancer patients: Activation potential and neutrophil extracellular trap formation	9
The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study	9
2B von Willebrand disease diagnosis: Considerations reflecting on 2021 multisociety guidelines	9
Generic PROMIS item banks in adults with hemophilia for patient‐reported outcome assessment: Feasibility, measurement properties, and relevance	9
New and known predictors of the postthrombotic syndrome: A subanalysis of the ATTRACT trial	9
Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial	9
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety	9
Thrombotic potential during pediatric acute lymphoblastic leukemia induction: Role of cell‐free DNA	9
Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between‐subject variation	9
Reproductive issues in women on direct oral anticoagulants	9
“If I wasn't a girl”: Experiences of adolescent girls with heavy menstrual bleeding and inherited bleeding disorders	9
Evaluating hemostatic thresholds for neuraxial anesthesia in adults with hemorrhagic disorders and tendencies: A scoping review	9
Disruptive technology and hemophilia care: The multiple impacts of emicizumab	9
Underrepresentation and undertreatment of women in hematology: An unsolved issue	9
Endothelial cell activation, Weibel-Palade body secretion, and enhanced angiogenesis in severe COVID-19	9
Thrombin generation and implications for hemophilia therapies: A narrative review	9
Thromboprophylaxis for children hospitalized with COVID‐19 and MIS‐C	9
Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort	9
Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination	9
Quantitative 3D microscopy highlights altered von Willebrand factor α‐granule storage in patients with von Willebrand disease with distinct pathogenic mechanisms	9
D‐dimer, thrombin generation, and risk of a first venous thrombosis in the elderly	9
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition	8
Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use	8
Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatment—A report from ICTHIC 2021	8
Thromboprophylaxis with rivaroxaban in patients with malignancy and central venous lines (TRIM‐Line): A two‐center open‐label pilot randomized controlled trial	8
Harnessing Twitter to empower scientific engagement and communication: The ISTH 2020 virtual congress experience	8
ADAMTS13 activity testing: evaluation of commercial platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura	8
Platelet reactivity and platelet count in women with iron deficiency treated with intravenous iron	8
A mixed‐methods study to evaluate a patient‐designed tool to reduce harm from cancer‐associated thrombosis: The EMPOWER study	8
Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study	8
The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste	8
Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield	8
Thrombosis and bleeding in patients with COVID-19 requiring extracorporeal membrane oxygenation: a systematic review and meta-analysis	8
Risk of thrombosis with thrombocytopenia syndrome after COVID‐19 vaccination prior to the recognition of vaccine‐induced thrombocytopenia and thrombosis: A self‐controlled case series study in England	8
Vaccine‐induced immune thrombotic thrombocytopenia with ChAdOx1 nCoV‐19 is rare in Asia	8
Association between cardiovascular risk factors and venous thromboembolism in the elderly	8
Inhibition of platelet adhesion, thrombus formation, and fibrin formation by a potent αIIbβ3 integrin inhibitor from ticks	8
Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune‐mediated thrombotic thrombocytopenic purpura in the United States	8
Characteristics and predictors of venous thrombosis recurrence in patients with cancer and catheter‐related thrombosis	8
Cryo‐EM structures of coagulation factors	8
Etiology and outcomes: Thrombotic microangiopathies in pregnancy	7
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study	7

Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors	7
Bradykinin – An elusive peptide in measuring and understanding	7
Long-term mortality in patients with pulmonary embolism: results in a single-center registry	7
Annual report on equity, diversity, and inclusion: Research and Practice in Thrombosis and Haemostasis is meeting its goals	7
Hemostatic phenotypes and genetic disorders	7
Tissue factor release following traumatic brain injury drives thrombin generation	7
Mim8, a novel factor VIIIa mimetic bispecific antibody, shows favorable safety and pharmacokinetics in healthy adults	7
Lupus anticoagulant associates with thrombosis in patients with COVID‐19 admitted to intensive care units: A retrospective cohort study	7
Management of heavy menstrual bleeding in women with bleeding disorders in a tertiary care center	7
Thrombus composition and thrombolysis resistance in stroke	7
Anticoagulant drug‐drug interactions: Highlighting the need for antithrombotic stewardship and shared decision making	7
Platelet Src family kinases: A tale of reversible phosphorylation	7
Hemostasis and tumor immunity	7
In patients with hemophilia, a decreased thrombin generation profile is associated with a severe bleeding phenotype	7
Sialic acid and platelet count regulation: Implications in immune thrombocytopenia	7
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies	7
Drug-drug interactions between direct oral anticoagulants and anticonvulsants and clinical outcomes: A systematic review	7
A microfluidic method to investigate platelet mechanotransduction under extensional strain	7
Fibronectin binding to von Willebrand factor occurs via the A1 domain	7
Low ADAMTS‐13 predicts adverse outcomes in hospitalized patients with suspected heparin‐induced thrombocytopenia	7
A hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders	7
New insight into the traditional model of the coagulation cascade and its regulation: illustrated review of a three-dimensional view	7
Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study	7
Fitness enhances psychosocial well‐being and self‐confidence in young men with hemophilia: Results from Project GYM	7
Fibrinolysis and bleeding of unknown cause	7
Challenges and knowledge gaps facing hemophilia carriers today: Perspectives from patients and health care providers	7
Anticoagulation stewardship: Descriptive analysis of a novel approach to appropriate anticoagulant prescription	7
Deep learning detects and visualizes bleeding events in electronic health records	7
Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study	7
Megakaryocytes in the lung: History and future perspectives	6
Forming megakaryocytes from murine induced pluripotent stem cells by the inducible overexpression of supporting factors	6
Compression stockings to prevent postthrombotic syndrome: Literature overview and presentation of the CELEST trial	6
Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing	6
eThrombosis: A new risk factor for venous thromboembolism in the pandemic era	6
MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study	6
Interlaboratory variability of activated protein C resistance using the ETP‐based APC resistance assay	6
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study	6
Overuse and underuse of thromboprophylaxis in medical inpatients	6
Knowledge and medication adherence of oral anticoagulant-taking patients in Vietnam	6
Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting	6
Nonreplacement therapy for hemophilia in low-income countries: experience from a prospective study in Ivory Coast	6
Thromboelastography determined dynamics of blood coagulation and its correlation with complications and outcomes in patients with coronavirus disease 2019	6
Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety	6
Clinical significance of subsegmental pulmonary embolism: An ongoing controversy	6
The von Willebrand factor – ADAMTS‐13 axis in malaria	6
Evaluation of a new bead‐based assay to measure levels of human tissue factor antigen in extracellular vesicles in plasma	6
Fibrin clot properties and thrombus composition in cirrhosis	6
Agreement of aptamer proteomics with standard methods for measuring venous thrombosis biomarkers	6
Tumor‐expressed microRNAs associated with venous thromboembolism in colorectal cancer	6
Updating the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT) in the era of extended half‐life clotting factor concentrates	6
Von Willebrand factor and the thrombophilia of severe COVID-19: in situ evidence from autopsies	6
Using an electronic medical record patient portal for warfarin self-management: Empowering children and parents	6
Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021	6
Assessing quality of life after pulmonary embolism: Comparing results from the PEmb‐QoL with semistructured interviews	6
Thromboembolic risk with gender-affirming hormone therapy: potential role of global coagulation and fibrinolysis assays	5
Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry	5
Lower levels of vWF are associated with lower risk of cardiovascular disease	5
Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists	5
Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A	5
Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy	5
Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin	5
Factor V Leiden but not the factor II 20210G>A mutation is a risk factor for premature coronary artery disease: a case-control study in Iran	5
Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia	5
Early SARS-CoV-2 infection: Platelet-neutrophil complexes and platelet function	5
Laboratory diagnosis of von Willebrand disease in the age of the new guidelines: considerations based on geography and resources	5
Abstracts	5
Exploring the utility of a novel point‐of‐care whole blood thrombin generation assay following trauma: A pilot study	5
Spatial transcriptomics of murine bone marrow megakaryocytes at single-cell resolution	5
Oral Communication abstracts	5
Cardiac surgery in acute heparin-induced thrombocytopenia managed with therapeutic plasma exchange and intravenous immunoglobulin	5
Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing	5
Complement factor C4a does not activate protease‐activated receptor 1 (PAR1) or PAR4 on human platelets	5
A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant	5
In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra	5
Laboratory-based inequity in thrombosis and hemostasis: review of the evidence	5
Response to rituximab in children and adults with immune thrombocytopenia (ITP)	5
Coagulation factor inhibitors in COVID‐19: From SARS‐CoV‐2 vaccination to infection	5
Poststroke venous thromboembolism and neutrophil activation: an illustrated review	5
Recurrent thrombosis rescued by fondaparinux in high‐risk patients: A case series	5
Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys	5
A systematic approach to venous thromboembolism prevention: a focus on UK experience	5
Do physicians contribute to psychological distress after venous thrombosis?	5
Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors	5
F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China	5
Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes	5
Incorporating the patient voice and patient engagement in GOAL‐Hēm: Advancing patient‐centric hemophilia care	5
Fishing for answers to hemostatic and thrombotic disease: Genome editing in zebrafish	5
Reliable measurement of plasma kinin peptides: Importance of preanalytical variables	5
Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis	5
Rivaroxaban in acute venous thromboembolism: UK prescribing experience	5
Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study	5
Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study	5
Health-related quality of life is impaired in bleeding disorders of unknown cause: results from the Vienna Bleeding Biobank	5
Detection of tissue factor–positive extracellular vesicles using the ExoView R100 system	5
Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: A systematic review	5